Thymic enlargement in a patient with juvenile idiopathic arthritis during etanercept therapy

被引：0

作者：

Ismail Sari

Omer Binicier

Merih Birlik

Servet Akar

Erkan Yilmaz

Aydanur Kargi

Fatos Onen

Nurullah Akkoc

机构：

[1] Dokuz Eylul University School of Medicine,Department of Internal Medicine, Division of Rheumatology

[2] Dokuz Eylul University School of Medicine,Department of Radiology

[3] Dokuz Eylul University School of Medicine,Department of Pathology

[4] Dokuz Eylul Universitesi Tip Fakultesi Ic hastaliklari ABD Immunoloji-Romatoloji,undefined

来源：

Rheumatology International | 2009年 / 29卷

关键词：

Tumor necrosis factor alpha inhibitors; Adverse effects;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Tumor necrosis factor (TNF) alpha inhibitors are effective in the treatment of inflammatory rheumatic diseases. Despite their effectiveness, anti-TNF drugs have some drawbacks such as severe adverse effects including infections and possibly lymphoproliferative disorders. In this report we described a case of juvenile idiopathic arthritis patient who developed thymic enlargement (true thymic hyperplasia), mediastinal lymphadenopathy and pleurisy associated with systemic symptoms under Etanercept treatment. The clinical presentation was highly suggestive of malignancy and the patient underwent diagnostic mediastinoscopy with biopsy.

引用

共 50 条

[41] Growth reconstitution in juvenile idiopathic arthritis treated with etanercept
Schmeling, H
Seliger, E
Horneff, G
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2003, 21 (06) : 779 - 784
[42] The German etanercept registry for treatment of juvenile idiopathic arthritis
Horneff, G
Schmeling, H
Biedermann, T
Foeldvari, I
Ganser, G
Girschick, HJ
Hospach, T
Huppertz, HI
Keitzer, R
Küster, RM
Michels, H
Moebius, D
Rogalski, B
Thon, A
ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 (12) : 1638 - 1644
[43] Etanercept treatment for children with refractory juvenile idiopathic arthritis
Kuo, Ho-Chang
Yu, Hong-Ren
Wu, Chih-Chiang
Chang, Ling-Sai
Yang, Kuender D.
JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION, 2011, 44 (01) : 52 - 56
[44] Psoriasis after treatment of juvenile idiopathic arthritis with etanercept
Peek, R.
Scott-Jupp, R.
Strike, H.
Clinch, J.
Ramanan, A. V.
ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (09) : 1259 - 1259
[45] Etanercept treatment in juvenile idiopathic arthritis: The Polish registry
Zuber, Zbigniew
Rutkowska-Sak, Lidia
Postepski, Jacek
Dobrzyniecka, Bogna
Opoka-Winiarska, Violetta
Kobusinska, Katarzyna
Gietka, Piotr
Osinska, Violetta
Turowska-Heydel, Dorota
Szczygielska, Izabela
Kolodziejczyk, Beata
Swiatek-Baczkowska, Anna
Gazda, Agnieszka
Wiland, Piotr
Tlustochowicz, Witold
Tuszkiewicz-Misztal, Ewa
MEDICAL SCIENCE MONITOR, 2011, 17 (12): : SR35 - SR42
[46] Guidelines on the use of etanercept for juvenile idiopathic arthritis in Japan
Yokota, Shumpei
Mori, Masaaki
Imagawa, Tomoyuki
Murata, Takuji
Tomiita, Minako
Itoh, Yasuhiko
Fujikawa, Satoshi
Takei, Syuji
MODERN RHEUMATOLOGY, 2010, 20 (02) : 107 - 113
[47] Anaphylaxis to Etanercept in Two Children With Juvenile Idiopathic Arthritis
Crayne, Courtney B.
Gerhold, Kerstin
Cron, Randy Q.
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2013, 19 (03) : 129 - 131
[48] Tumour necrosis factor alpha promoter polymorphisms and etanercept therapy in juvenile idiopathic arthritis
Schmeling, Heinrike
Horneff, Gerd
RHEUMATOLOGY INTERNATIONAL, 2007, 27 (04) : 383 - 386
[49] Chronic inflammatory demyelinating neuropathy after etanercept therapy in the course of juvenile idiopathic arthritis
Genc, Huelya Maras
Kutlubay, Busra
Surmeli, Reyhan
Sozen, Hatice Gulhan
Sozeri, Betul
TURKISH JOURNAL OF PEDIATRICS, 2023, 65 (01) : 165 - 169
[50] Tumour necrosis factor alpha promoter polymorphisms and etanercept therapy in juvenile idiopathic arthritis
Heinrike Schmeling
Gerd Horneff
Rheumatology International, 2007, 27 : 383 - 386

← 1 2 3 4 5 →